Omega Diagnostics Share Discussion Threads

[nigelwestm] 16/10/2009 11:20

Any reason why this has shot up 30% today? There doesn't seem to be an RNS or news...

[abbey8] 16/10/2009 08:31

Thank you.

[gary1966] 15/10/2009 23:43

abbey8,

27/11/2009

[abbey8] 03/10/2009 14:06

any idea when the result out.Thanks

[this_is_me] 25/9/2009 08:07

Private investors shafted again by a placing under the bid. I have sent an e-mail to the chairman complaining.


David Evans, CA, Non-Executive Chairman

[e-mail]

[guman] 01/8/2009 16:10

for interest as reported in aimzine
Omega Diagnostics Group

Producing Strong Global Growth
RETURN TO AIMZINE NEWSLETTER HOME | August 2009
Code: ODX
Sector: Health Care - Medical Supplies
Price:25p Market Cap: £3.9 million
Locations: Stirling and Cambridge Number of Staff: 58 (including directors)

Tucked away amongst AIM's smaller companies are some fascinating prospects. With a Market Cap of just under £4 million and recently reporting strong organic growth, we believe that Omega Diagnostics could have a very exciting future in store.
In August 2007 Omega Diagnostics completed an acquisition of two linked companies: Genesis Diagnostics and Cambridge Nutritional Sciences (CNS). The acquisition was described at the time as 'highly significant' and two years later this is proving to be the case, as there has been excellent performances reported from these acquired companies. I spoke with Finance Director, Kieron Harbinson, who believes that there is considerable potential for further growth both from the acquired companies and from the original Omega Diagnostics business.

[guman] 02/7/2009 15:55

tdw showing change -1.13,how do they do it?
most of changes shown are wrong.

[smiler_o] 12/3/2009 10:22

Aye, But still some have done a lot worse, This is a steady little Co !!

[guman] 02/2/2009 21:39

no body seems to be interested in this company,unique.

[gadg3t] 18/7/2008 11:38

Omega Diagnostics returns to profitability

Medical diagnostics company, Omega Diagnostics Group, this morning reported a return to full-year profitability, benefiting from recent acquisitions, and said it remains confident of its growth prospects for the year ahead.

For the year to March 31st, 2008, the company posted a pretax profit of £124,000 compared with a loss of £1.14m a year earlier.

Revenue grew to £3.49m from £2.03m.

Chairman David Evans said: 'I am pleased to say that the first three months of the year are in line with expectation.'

Turnover for the first three months of the current year is £1.36m, 23% ahead of an equivalent pro-forma number for the comparative period last year.




RNS Number : 3906Z
Omega Diagnostics Group PLC
18 July 2008



Omega Diagnostics Group PLC



18 July 2008




Omega Diagnostics Group PLC ('the Company')




Annual Report & Accounts




Omega Diagnostics Group PLC announces that its annual report & accounts for the year ended 31 March 2008 have been posted to shareholders. Copies of the report & accounts will be available on the Company's website www.omegadiagnostics.com

[gadg3t] 07/7/2008 07:38

Thanks for posting Knowing...

[knowing] 07/7/2008 07:15

7 July 2008

OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company")

FINAL RESULTS
FOR THE YEAR ENDED 31 MARCH 2008

Omega, the AIM listed medical diagnostics company, announces results for the year ended 31
March 2008, a year of progress in which the
company completed its first acquisition and returned to profitability.

Omega is a medical diagnostics company and one of the UK's leading companies in the fast
growing area of food intolerance testing where
its multiple platform technologies offer competitive advantage. Omega's strong global
distribution network (over 100 countries) offers a
conduit to market not only for its food intolerance tests but also its autoimmune and
infectious disease product ranges.

Financial Summary:
Year to Year to
31 March 31 March
2008 2007

Revenue 3,491,580 2,032,146
Gross profit 1,897,894 831,489
Operating profit/(loss) 298,237 (885,652)

Profit/(loss) before tax 123,708 (1,141,225)

2008 Highlights:

· Acquisition of Genesis Diagnostics Ltd and Cambridge Nutritional Sciences Ltd for
an initial consideration of £5.7m.
· £2.2m new equity (before expenses) raised via a cash placing of 7,333,333 new
ordinary shares at 30p a share.
· Appointment of Dr Mike Walker as new Non-Executive Director.
· The acquisition of Genesis and CNS in line with Omega*s strategy to become a
leading in-vitro diagnostics company through
selective acquisitions of companies with complementary strengths.
· Genesis-CNS acquisition provides major growth opportunity to develop new products
using two key technologies, the macroarray and
microarray.
· Completion of HSV2 product development.


Regarding outlook, David Evans, Chairman, said:

"Having completed on our first acquisition last year the forthcoming year is essentially
about two objectives; firstly the delivery of
both top line and bottom line growth in turnover and profitability and I am pleased to say
that the first three months of the year are in
line with expectation. Turnover for the first three months is £1,363k which is 23% ahead of
an equivalent pro-forma number for the
comparative period last year. Secondly, we must deliver on our stated objective of growth
through acquisition although in the current
funding environment this is likely to be a more challenging task and demands more creative
solutions in order to deliver value to all
shareholders."

[knowing] 24/4/2008 21:00

Simon can you email me at [e-mail]

[simon_64] 24/4/2008 20:15

Knowing

What threads are you on mate ?

[knowing] 10/4/2008 08:06

RNS Number:0440S
Omega Diagnostics Group PLC
10 April 2008




Omega Diagnostics Group PLC
('Omega' or 'the Group)

Trading Update


Omega, the AIM listed medical diagnostics company, announces that trading for
the year ended 31st March 2008 was in line with market expectations with
turnover showing an increase for the year of circa 70% over the previous year
(year ended 31st March 2007: £2.03m).


The increase in turnover follows the acquisition of Genesis Diagnostics Ltd and
Cambridge Nutritional Sciences Ltd in September 2007 which contributed around
68% of the growth, and organic growth of around 2%.


The directors are confident for the prospects of the Group for the new financial
year and the Group will announce its results for the year ended 31st March 2008
during July 2008.


Contacts:


Omega Diagnostics Group PLC Landsbanki Securities Parkgreen Communications
(UK) Limited

Andrew Shepherd, Chief Executive Thilo Hoffmann Ben Knowles
Kieron Harbinson, Finance Director
Simon Brown
Tel: [phone] 020 7426 9000 Tel: [phone]
www.omegadiagnostics.com Mob: [phone]

[e-mail]

[knowing] 12/3/2008 13:38

Another Director buy.

[smiler 0] 12/3/2008 12:45

up 8% again today at Mo !! :)

[gadg3t] 12/3/2008 10:20

10p in 3 months not bad at all IMO !!

[smiler 0] 11/3/2008 20:08

Yes good to see & about time !!!